Biotech · Private company

Newave Pharmaceutical Inc

Track this companyFree. Adds Newave Pharmaceutical Inc to your Dealase workspace and tells you when its record changes.

Clinical trials65 recruiting or active

Pipeline programs6From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline6

A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)PHASE1 · RECRUITING · started Dec 1, 2026ClinicalTrials.gov NCT07614022 · fetched Nov 12, 2026
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLPHASE3 · RECRUITING · started Apr 23, 2026ClinicalTrials.gov NCT07342478 · fetched Nov 12, 2026
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of ThisPHASE2 · RECRUITING · started Jun 1, 2025ClinicalTrials.gov NCT06978088 · fetched Nov 12, 2026
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.PHASE1 · RECRUITING · started May 8, 2022ClinicalTrials.gov NCT04771572 · fetched Nov 12, 2026
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.PHASE1 · RECRUITING · started Jul 19, 2021ClinicalTrials.gov NCT04775745 · fetched Nov 12, 2026
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AMLPHASE1 · COMPLETED · started Jul 6, 2020ClinicalTrials.gov NCT04139434 · fetched Nov 12, 2026